Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355261 | 0.84 | CXCR5 (0.44) | LMNAMAPK10SCN9ASLC6A9TACR3 | |
| SCHEMBL4356991 | 0.84 | SCN9A (0.49) | LMNASCN9ASLC6A9TACR3 | |
| SCHEMBL4359374 | 0.84 | SLC6A9 (0.41) | LMNASCN9ASLC6A9TACR3 | |
| SCHEMBL4357362 | 0.82 | PLK1 (0.50) | LMNASCN9AALDH1A1SLC6A9TACR3 | |
| SCHEMBL4352703 | 0.77 | PREP (0.49) | SLC6A9TACR3 | |
| SCHEMBL4361757 | 0.77 | NCEH1 (0.40) | LMNAALDH1A1SLC6A9TACR3 | |
| SCHEMBL3237287 | 0.77 | SLC6A9 (0.45) | LMNASLC6A9 | |
| SCHEMBL3244640 | 0.77 | SLC6A9 (0.42) | LMNAALDH1A1SLC6A9 | |
| SCHEMBL3236131 | 0.76 | ALDH1A1 (0.41) | LMNAALDH1A1SLC6A9 | |
| SCHEMBL3255543 | 0.76 | KMT2A (0.46) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | SLC22A12 761/4885LMNA 4046/4885MAPK10 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.